Skip to main content

Advertisement

SpringerLink
Log in

High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171(2):481–494.e15. https://doi.org/10.1016/j.cell.2017.09.027

    Article  CAS  PubMed  Google Scholar 

  2. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905–6913. https://doi.org/10.4049/jimmunol.1100274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034. https://doi.org/10.1084/jem.192.7.1027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus associated malignancies. Clin Cancer Res 19(13):3462–3473. https://doi.org/10.1158/1078-0432.CCR-13-0855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G et al (2014) High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 28(12):2367–2375. https://doi.org/10.1038/leu.2014.137

    Article  CAS  PubMed  Google Scholar 

  7. Imawari Y, Mimoto R, Hirooka S, Morikawa T, Takeyama H, Yoshida K (2017) Downregulation of DYRK2 promotes tumor cell proliferation and invasion by enhancing CDK14 expression in breast cancer. Cancer Sci. https://doi.org/10.1111/cas.13459

  8. Huang R, Zhang D, Li F, Xiao Z, Wu M, Shi D, Xiang P, Bao Z (2017) Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett 13(5):3379–3386. https://doi.org/10.3892/ol.2017.5891

    Article  PubMed  PubMed Central  Google Scholar 

  9. Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P (2016) FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood 127(6):739–748. https://doi.org/10.1182/blood-2015-06-654111

    Article  CAS  PubMed  Google Scholar 

  10. Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK (2015) MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 6(17):15035–15049. https://doi.org/10.18632/oncotarget.3729

    Article  PubMed  PubMed Central  Google Scholar 

  11. Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, O'Sullivan MG, Weissman IL, Modiano JF (2016) Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol Res 4(12):1072–1087. https://doi.org/10.1158/2326-6066.CIR-16-0105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193–2201. https://doi.org/10.1182/blood-2015-02-629600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16(5):e234–e245. https://doi.org/10.1016/S1470-2045(15)70103-8

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by grants from the China Doctoral Program Fund (Doctoral Advisor, 20130001110090) and the National Natural Science Foundation of China (81500118, 61501519).

Author information

Author notes

  1. Jinlong Shi, Xiaoyan Ke and Lin Fu are senior authors who contributed equally to this work and share corresponding author.

Authors and Affiliations

  1. Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China

    Zhiheng Cheng, Jing Wang, Xiaoyan Ke & Lin Fu

  2. Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, 475000, China

    Zhiheng Cheng & Jinlong Shi

  3. Laboratory of Environmental Medicine and Developmental Toxicology, Shantou University Medical College, Shantou, 515041, China

    Yifeng Dai

  4. Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China

    Jinlong Shi

  5. Department of Medical Big Data, Chinese PLA General Hospital, Beijing, 100853, China

    Jinlong Shi

Authors
  1. Zhiheng Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yifeng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinlong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoyan Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LF, XYK, and JLS conceived the study, participated in its design and coordination, and collected data. ZHC mainly participated in statistical analysis and drafted the manuscript. YFD and JW were mainly responsible for the collection of literature.

Corresponding authors

Correspondence to Jinlong Shi, Xiaoyan Ke or Lin Fu.

Ethics declarations

Ethics approval and consent to participate

All data in this study were downloaded from the Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo, GSE10846). We did not involve direct interaction with patients. So, this study did not involve ethics approval and consent to participate.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, Z., Dai, Y., Wang, J. et al. High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma. Ann Hematol 97, 1085–1088 (2018). https://doi.org/10.1007/s00277-018-3266-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3266-0

Search

Navigation